{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T08:54:55Z","timestamp":1775984095420,"version":"3.50.1"},"reference-count":50,"publisher":"Japanese Society of Internal Medicine","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2024,7,1]]},"DOI":"10.2169\/internalmedicine.2556-23","type":"journal-article","created":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T22:15:28Z","timestamp":1719785728000},"page":"1863-1872","source":"Crossref","is-referenced-by-count":3,"title":["Activated CD4&lt;sup&gt;+&lt;\/sup&gt; T Cell Proportion in the Peripheral Blood Correlates with the Duration of Cytokine Release Syndrome and Predicts Clinical Outcome after Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.2169","volume":"63","author":[{"given":"Wataru","family":"Kitamura","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Ikegawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"},{"name":"Division of Blood Transfusion, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Kamoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"},{"name":"Division of Blood Transfusion, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[{"name":"Center for Comprehensive Genomic Medicine, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisakazu","family":"Nishimori","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Clinical Laboratory, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[{"name":"Division of Blood Transfusion, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380: 45-56, 2019.","DOI":"10.1056\/NEJMoa1804980"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377: 2531-2544, 2017.","DOI":"10.1056\/NEJMoa1707447"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396: 839-852, 2020.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol 32: 34-48, 2021.","DOI":"10.1016\/j.annonc.2020.10.478"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Varadarajan I, Lee DW. Management of T-cell engaging immunotherapy complications. Cancer J 25: 223-230, 2019.","DOI":"10.1097\/PPO.0000000000000377"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54: 1643-1650, 2019.","DOI":"10.1038\/s41409-019-0487-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nahas GR, Komanduri KV, Pereira D, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma 61: 940-943, 2020.","DOI":"10.1080\/10428194.2019.1697814"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv 4: 3776-3787, 2020.","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Strati P, Varma A, Adkins S, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106: 2667-2672, 2021.","DOI":"10.3324\/haematol.2020.254045"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nagle SJ, Murphree C, Raess PW, et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol 96: 455-461, 2021.","DOI":"10.1002\/ajh.26113"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma. Blood 138: 2499-2513, 2021.","DOI":"10.1182\/blood.2020010543"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Juluri KR, Wu QV, Voutsinas J, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv 6: 2055-2068, 2022.","DOI":"10.1182\/bloodadvances.2020004142"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371: 1507-1517, 2014.","DOI":"10.1056\/NEJMoa1407222"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wang Y, Zhang WY, Han QW, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 155: 160-175, 2014.","DOI":"10.1016\/j.clim.2014.10.002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130: 2295-2306, 2017.","DOI":"10.1182\/blood-2017-06-793141"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 19: 867-880, 2017.","DOI":"10.1016\/j.jcyt.2017.04.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J Biol Chem 294: 5430-5437, 2019.","DOI":"10.1074\/jbc.AC119.007558"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24: 739-748, 2018.","DOI":"10.1038\/s41591-018-0036-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med 24: 731-738, 2018.","DOI":"10.1038\/s41591-018-0041-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 26: 1878-1887, 2020.","DOI":"10.1038\/s41591-020-1061-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-656, 1982.","DOI":"10.1097\/00000421-198212000-00014"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-282, 2004.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32: 3059-3067, 2014.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25: 625-638, 2019.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56: 337-344, 2000.","DOI":"10.1111\/j.0006-341X.2000.00337.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wing JB, Tanaka A, Sakaguchi S. Human FOXP3<sup>+<\/sup> regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity 50: 302-316, 2019.","DOI":"10.1016\/j.immuni.2019.01.020"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203: 1693-1700, 2006.","DOI":"10.1084\/jem.20060468"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172-3177, 1985.","DOI":"10.4049\/jimmunol.135.5.3172"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Sallusto F, Lenig D, F\u00f6rster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712, 1999.","DOI":"10.1038\/44385"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687, 2006.","DOI":"10.1038\/nature04444"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lamure S, Van Laethem F, De Verbizier D, et al. Clinical and product features associated with outcome of DLBCL patients to CD19-targeted CAR T-cell therapy. Cancers (Basel) 13: 4279, 2021.","DOI":"10.3390\/cancers13174279"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Monfrini C, Stella F, Aragona V, et al. Phenotypic composition of commercial anti-CD19 CAR T cells affects <i>in vivo<\/i> expansion and disease response in patients with large B-cell lymphoma. Clin Cancer Res 28: 3378-3386, 2022.","DOI":"10.1158\/1078-0432.CCR-22-0164"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Haradhvala NJ, Leick MB, Maurer K, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med 28: 1848-1859, 2022.","DOI":"10.1038\/s41591-022-01959-0"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Garcia-Calderon CB, Sierro-Martinez B, Garcia-Guerrero E, et al. Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies. Front Immunol 14: 1152498, 2023.","DOI":"10.3389\/fimmu.2023.1152498"},{"key":"35","unstructured":"35. Hanajiri R, Furukawa K, Nakashima M, et al. Cellular kinetics and outcome of tisagenlecleucel for diffuse large B-cell lymphoma. Rinsho Ketsueki (Jpn J Clin Hematol) 64: 167-174, 2023 (in Japanese)."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kauer J, Horner S, Osburg L, et al. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer 8: 2020.","DOI":"10.1136\/jitc-2020-000621"},{"key":"37","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2249.1996.tb08306.x","volume":"103","author":"L Lanza","year":"1996","unstructured":"37. Lanza L, Scudeletti M, Puppo F, et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol 103: 482-490, 1996.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Davis TE, Kis-Toth K, Szanto A, Tsokos GC. Glucocorticoids suppress T cell function by up-regulating microRNA-98. Arthritis Rheum 65: 1882-1890, 2013.","DOI":"10.1002\/art.37966"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4<sup>+<\/sup>:CD8<sup>+<\/sup> composition in adult B cell ALL patients. J Clin Invest 126: 2123-2138, 2016.","DOI":"10.1172\/JCI85309"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6: 664-679, 2016.","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 383: 2255-2273, 2020.","DOI":"10.1056\/NEJMra2026131"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173, 1989.","DOI":"10.1146\/annurev.iy.07.040189.001045"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Wei J, Liu Y, Wang C, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther 5: 134, 2020.","DOI":"10.1038\/s41392-020-00256-x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 8: 523-532, 2008.","DOI":"10.1038\/nri2343"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Lin S, Wu H, Wang C, Xiao Z, Xu F. Regulatory T cells and acute lung injury: cytokines, uncontrolled inflammation, and therapeutic implications. Front Immunol 9: 1545, 2018.","DOI":"10.3389\/fimmu.2018.01545"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4: 4898-4911, 2020.","DOI":"10.1182\/bloodadvances.2020002394"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Hirayama A, Gauthier J, Hay K, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133: 1876-1887, 2019.","DOI":"10.1182\/blood-2018-11-887067"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Batsivari A, Haltalli MLR, Passaro D, Pospori C, Lo Celso C, Bonnet D. Dynamic responses of the haematopoietic stem cell niche to diverse stresses. Nat Cell Biol 22: 7-17, 2020.","DOI":"10.1038\/s41556-019-0444-9"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Lutfi F, Holtzman NG, Kansagra AJ, et al. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma. Br J Haematol 195: 405-412, 2021.","DOI":"10.1111\/bjh.17738"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Turtle C, Hanafi L, Berger C, et al. Immunotherapy of non-Hodgkin&apos;s lymphoma with a defined ratio of CD8<sup>+<\/sup> and CD4<sup>+<\/sup> CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8: 355ra116, 2016.","DOI":"10.1126\/scitranslmed.aaf8621"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/13\/63_2556-23\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T03:44:50Z","timestamp":1732333490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/63\/13\/63_2556-23\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":50,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2556-23","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"article-number":"2556-23"}}